Cytori Reports First Quarter 2015 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Ascendiant Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
May 12, 2015 6:55 AM EDTAscendiant Capital initiated coverage on Cytori Therapeutics, Inc. (NASDAQ: CYTX) with a Buy rating and a price target of $1.25.
For an analyst ratings summary and ratings history on Cytori Therapeutics, Inc. click... More
Cytori Therapeutics (CYTX) Reports In-Line Q1 Loss of 7c/Share
May 11, 2015 4:23 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $2.44 million.
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
... More